Ottaiano, A.; Santorsola, M.; Perri, F.; Granata, V.; Cascella, M.; Sabbatino, F.; Nasti, G.
Survival and Toxicities of Metastatic Colorectal Cancer Patients Treated with Regorafenib before TAS-102 or Vice Versa: A Mono-Institutional Real-Practice Study. J. Clin. Med. 2023, 12, 596.
https://doi.org/10.3390/jcm12020596
AMA Style
Ottaiano A, Santorsola M, Perri F, Granata V, Cascella M, Sabbatino F, Nasti G.
Survival and Toxicities of Metastatic Colorectal Cancer Patients Treated with Regorafenib before TAS-102 or Vice Versa: A Mono-Institutional Real-Practice Study. Journal of Clinical Medicine. 2023; 12(2):596.
https://doi.org/10.3390/jcm12020596
Chicago/Turabian Style
Ottaiano, Alessandro, Mariachiara Santorsola, Francesco Perri, Vincenza Granata, Marco Cascella, Francesco Sabbatino, and Guglielmo Nasti.
2023. "Survival and Toxicities of Metastatic Colorectal Cancer Patients Treated with Regorafenib before TAS-102 or Vice Versa: A Mono-Institutional Real-Practice Study" Journal of Clinical Medicine 12, no. 2: 596.
https://doi.org/10.3390/jcm12020596
APA Style
Ottaiano, A., Santorsola, M., Perri, F., Granata, V., Cascella, M., Sabbatino, F., & Nasti, G.
(2023). Survival and Toxicities of Metastatic Colorectal Cancer Patients Treated with Regorafenib before TAS-102 or Vice Versa: A Mono-Institutional Real-Practice Study. Journal of Clinical Medicine, 12(2), 596.
https://doi.org/10.3390/jcm12020596